Acurx Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized**.**
| | ACURX PHARMACEUTICALS, INC. | |
|---|---|---|
| Date: March 15, 2024 | By: | /s/ David P. Luci |
| | | David P. Luci |
| | | President and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date | ||
|---|---|---|---|---|
| | | | | |
| /s/ David P. Luci | | President, Chief Executive Officer and Director | | March 15, 2024 |
| David P. Luci | (Principal Executive Officer) | |||
| | | | | |
| /s/ Robert G. Shawah | | Chief Financial Officer | | March 15, 2024 |
| Robert G. Shawah | (Principal Accounting Officer and Principal Financial Officer) | |||
| | | | | |
| /s/ Robert J. DeLuccia | | Executive Chairman | | March 15, 2024 |
| Robert J. DeLuccia | | | | |
| | | | | |
| /s/ Carl V. Sailer | | Director | | March 15, 2024 |
| Carl V. Sailer | | | | |
| | | | | |
| /s/ Joseph C. Scodari | | Director | | March 15, 2024 |
| Joseph C. Scodari | | | | |
| | | | | |
| /s/ Thomas Harrison | | Director | | March 15, 2024 |
| Thomas Harrison | | | | |
| | | | | |
| /s/ Jack H. Dean | | Director | | March 15, 2024 |
| Jack H. Dean | | | | |
| | | | | |
| /s/ James Donohue | | Director | | March 15, 2024 |
| James Donohue | | | | |
INDEX TO FINANCIAL STATEMENTS
| Years Ended December 31, 2023 and 2022 | Page | |
|---|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 596) | | F-2 |
| Balance Sheets | | F-3 |
| Statements of Operations | | F-4 |
| Statements of Changes in Shareholders’ Equity | | F-5 |
| Statements of Cash Flows | | F-6 |
| Notes to Financial Statements | | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.